Jaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and People

Diarrhea is a highly neglected and unmet burden of cancer treatment in both people and dogs; A Jaguar-sponsored Gallup survey found that the incidence of U.S. dogs diagnosed with cancer in 2021 was approximately five times the incidence of cancer diagnosed in people

SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2023 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company is launching an AI-driven series of disease awareness educational content on social media regarding cancer therapy-related diarrhea in dogs and people. The series will also include content about HIV-related diarrhea in humans.

"Diarrhea is a highly neglected and unmet burden of cancer treatment in both people and dogs, and more than half of people living with HIV have experienced chronic, or long-term, diarrhea that is serious enough to negatively impact their quality of life. Leveraging artificial intelligence (AI) technology, like OpenAI's generative AI language model ChatGPT, will allow us to generate and share educational information about these therapeutic areas, as relevant, with patient and healthcare practitioner communities, dog owners, and veterinarians across Company social media channels," said Ian H. Wendt, Jaguar's Chief Commercial Officer.

"A 2022 Jaguar-sponsored Gallup Survey found that the incidence - the percent of U.S. dogs newly diagnosed with cancer in 2021 - was 2.8 percent, which is approximately five times the 0.57 percent incidence of newly diagnosed cancer in humans that year," said Lisa Conte, Jaguar's founder, president and CEO. "This finding is startling since researchers have assumed that canine cancer rates mirror human cancer rates."

About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will launch an AI-driven series of disease awareness educational content on social media regarding cancer therapy-related diarrhea in dogs and people, and that the series will also include content about HIV-related diarrhea in humans.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.